MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Read moreMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Read moreMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Read moreOncology Focused, Patient Centric
We are committed to the development of novel and differentiated cancer therapies intended to provide improved outcomes to patients